Pandemrix vaccine: why was the public not told of early warning signs?
dc.contributor.author | Doshi, Peter | |
dc.date.accessioned | 2018-09-24T17:55:54Z | |
dc.date.available | 2018-09-24T17:55:54Z | |
dc.date.issued | 2018-09-20 | |
dc.identifier.citation | Doshi, P. (2018). Pandemrix vaccine: why was the public not told of early warning signs? BMJ, 362:k3948. doi: 10.1136/bmj.k3948 | en_US |
dc.identifier.uri | http://hdl.handle.net/10713/8270 | |
dc.description.abstract | Eight years after the pandemic influenza outbreak, a lawsuit alleging that GlaxoSmithKline’s Pandemrix vaccine caused narcolepsy has unearthed internal reports suggesting problems with the vaccine’s safety. Peter Doshi asks what this means for the future of transparency during public health emergencies. | en_US |
dc.description.uri | http://bmj.com/cgi/content/full/bmj.k3948?ijkey=Q078zFNInyGN8CS&keytype=ref | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | BMJ Publishing Group | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Pandemrix | en_US |
dc.subject.lcsh | GlaxoSmithKline | en_US |
dc.subject.mesh | Disclosure | en_US |
dc.subject.mesh | Drug Evaluation | en_US |
dc.subject.mesh | Immunization Programs--ethics | en_US |
dc.subject.mesh | Influenza Vaccines--adverse effects | en_US |
dc.title | Pandemrix vaccine: why was the public not told of early warning signs? | en_US |
dc.type | Article | en_US |
dc.description.version | Yes | en_US |
dc.identifier.pmid | 30237282 | |
dc.identifier.ispublished | No | en_US |
dc.description.uriname | Click here for the free full-text article on publisher’s website | en_US |
refterms.dateFOA | 2019-02-19T17:57:34Z |